AVEO Pharmaceuticals, Inc. (AVEO) Income Statement Analysis

See more : Aditya Vision Limited (AVL.BO) Income Statement Analysis – Financial Results

Complete financial analysis of AVEO Pharmaceuticals, Inc. (AVEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVEO Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Aerkomm Inc. (AKOM.PA) Income Statement Analysis – Financial Results
Atlantic Union Bankshares Corporation (AUBAP) Income Statement Analysis – Financial Results
Henan Yicheng New Energy Co., Ltd. (300080.SZ) Income Statement Analysis – Financial Results
JLEN Environmental Assets Group Limited (JLEN.L) Income Statement Analysis – Financial Results
Pancontinental Resources Corporation (PUCCF) Income Statement Analysis – Financial Results

AVEO Pharmaceuticals, Inc. (AVEO)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.aveooncology.com

About AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Metric	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	38.87M	6.02M	28.80M	5.41M	7.58M	2.52M	19.02M	18.12M	1.29M	19.29M	164.85M	44.68M	20.72M	19.66M	11.03M
Cost of Revenue	4.74M	1.25M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	34.14M	4.77M	28.80M	5.41M	7.58M	2.52M	19.02M	18.12M	1.29M	19.29M	164.85M	44.68M	20.72M	19.66M	11.03M
Gross Profit Ratio	87.81%	79.32%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Research & Development	26.30M	22.68M	17.96M	20.65M	25.18M	23.70M	12.88M	38.25M	68.47M	91.36M	101.74M	86.35M	51.79M	41.82M	29.25M
General & Administrative	0.00	22.22M	11.21M	10.78M	9.14M	8.21M	14.22M	18.59M	28.71M	36.93M	29.17M	14.76M	10.12M	9.16M	6.50M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	60.81M	22.22M	11.21M	10.78M	9.14M	8.21M	14.22M	18.59M	28.71M	36.93M	29.17M	14.76M	10.12M	9.16M	6.50M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	4.36M	11.73M	8.02M	2.63M	0.00	0.00	0.00	0.00	0.00
Operating Expenses	87.11M	44.90M	29.17M	31.43M	34.32M	31.91M	27.09M	56.84M	97.18M	128.29M	130.90M	101.11M	61.91M	50.99M	35.75M
Cost & Expenses	91.85M	44.90M	29.17M	31.43M	34.32M	31.91M	27.09M	56.84M	97.18M	128.29M	130.90M	101.11M	61.91M	50.99M	35.75M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	21.00K	32.00K	125.00K	497.00K	527.00K	126.00K	144.26K	1.17M	2.17M
Interest Expense	-4.05M	1.61M	1.82M	2.19M	2.37M	1.95M	2.31M	2.39M	3.13M	3.50M	3.84M	3.39M	2.81M	2.09M	2.44M
Depreciation & Amortization	-7.83M	21.00K	11.58M	22.22M	-33.74M	30.00K	9.57M	6.22M	3.78M	2.51M	1.65M	1.35M	1.29M	1.32M	1.33M
EBITDA	-57.39M	-33.96M	11.20M	-3.14M	-62.55M	-24.81M	-3.13M	-44.13M	-100.13M	-108.38M	36.14M	-54.05M	-40.09M	-29.07M	-21.21M
EBITDA Ratio	-147.62%	-564.18%	38.91%	-58.01%	-825.32%	-986.36%	-16.44%	-243.51%	-7,743.77%	-561.98%	21.92%	-120.97%	-193.52%	-147.84%	-192.22%
Operating Income	-49.55M	-38.88M	-374.00K	-25.36M	-28.81M	-29.39M	-12.43M	-50.45M	-103.90M	-111.64M	33.95M	-56.43M	-41.19M	-31.33M	-24.72M
Operating Income Ratio	-127.47%	-645.90%	-1.30%	-468.79%	-380.14%	-1,168.71%	-65.32%	-278.37%	-8,035.89%	-578.85%	20.59%	-126.28%	-198.83%	-159.33%	-223.99%
Total Other Income/Expenses	-3.79M	3.29M	9.76M	20.03M	-36.11M	2.61M	-2.58M	-2.29M	-3.13M	-2.76M	-3.30M	-2.36M	-3.00M	-1.15M	-266.03K
Income Before Tax	-53.34M	-35.58M	9.39M	-5.33M	-64.92M	-26.79M	-15.00M	-52.74M	-107.03M	-114.39M	30.65M	-58.79M	-44.19M	-32.47M	-24.98M
Income Before Tax Ratio	-137.22%	-591.19%	32.60%	-98.52%	-856.63%	-1,065.05%	-78.85%	-291.01%	-8,277.57%	-593.15%	18.59%	-131.57%	-213.30%	-165.17%	-226.40%
Income Tax Expense	7.83M	4.90M	0.00	0.00	101.00K	101.00K	-268.00K	98.00K	2.00K	744.00K	537.00K	1.03M	-100.06K	937.81K	2.17M
Net Income	-61.18M	-35.58M	9.39M	-5.33M	-65.03M	-26.89M	-15.00M	-52.74M	-107.03M	-114.39M	30.65M	-58.79M	-44.09M	-32.47M	-24.98M
Net Income Ratio	-157.37%	-591.19%	32.60%	-98.52%	-857.96%	-1,069.07%	-78.85%	-291.01%	-8,277.57%	-593.15%	18.59%	-131.57%	-212.82%	-165.17%	-226.40%
EPS	-2.86	-1.66	0.61	-0.41	-6.14	-3.88	-2.69	-10.09	-21.02	-26.37	7.72	-22.98	-22.31	-202.07	-155.46
EPS Diluted	-2.86	-1.66	0.61	-0.41	-6.14	-3.88	-2.69	-10.09	-21.02	-26.37	7.39	-22.98	-22.31	-202.07	-155.46
Weighted Avg Shares Out	21.40M	21.40M	15.38M	13.07M	10.59M	6.93M	5.57M	5.23M	5.09M	4.34M	3.97M	2.56M	1.98M	160.70K	160.70K
Weighted Avg Shares Out (Dil)	21.40M	21.40M	15.38M	13.07M	10.59M	6.93M	5.57M	5.23M	5.09M	4.34M	4.15M	2.56M	1.98M	160.70K	160.70K

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

March 28, 2024globenewswire.com

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

March 25, 2024globenewswire.com

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

February 6, 2024globenewswire.com

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology , an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial...

AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

January 16, 2024globenewswire.com

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with...